Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 78 Forward PE Ratio is 21.34 as of Aug. 01, 2026. GuruFocus rates REVXF with a GF Score™ of 78/100 and a GF Value™ of $41.40 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 390 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 52.31% on this metric.
Revenio Group Oyj (OTCPK:REVXF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Revenio Group Oyj Forward PE Ratio Related Terms
Revenio Group Oyj Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revenio Group Oyj Forward PE Ratio Chart
Revenio Group Oyj Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
27.57
21.37
Revenio Group Oyj Quarterly Data
2024-03
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
32.36
27.57
29.98
32.51
23.13
21.37
25.61
REVXF vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, Revenio Group Oyj's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Revenio Group Oyj (REVXF) has a Forward PE Ratio of 21.34 as of Aug. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Revenio Group Oyj and its competitors. According to the industry distribution chart, Revenio Group Oyj ranks #186 out of 390 companies in the Medical Devices & Instruments industry, placing it in the top 47.7%.
Is Revenio Group Oyj's Forward PE Ratio too high?
Revenio Group Oyj's current Forward PE Ratio is 21.34. The Medical Devices & Instruments industry median Forward PE Ratio is 19.45. Revenio Group Oyj's value of 21.34 is 9.7% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #186 out of 390 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Revenio Group Oyj has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #186 out of 390 companies for Forward PE Ratio. This puts Revenio Group Oyj in the upper half of its industry. The industry median Forward PE Ratio is 19.45. Revenio Group Oyj's value of 21.34 is 9.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.45, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current Forward PE Ratio of 21.34 is 9.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current Forward PE Ratio is 21.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (REVXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.40, compared to a current price of $16.41 — trading 60.4% below its estimated fair value. The current Forward PE Ratio is 21.34 and 9.7% above the Medical Devices & Instruments industry median of 19.45. Revenio Group Oyj's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current Forward PE Ratio is 21.34 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 60.4% below its estimated GF Value™ of $41.40.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for REVXF:
Forward PE Ratio: 21.34
GF Value™: $41.40 vs. price of $16.41 (60.4% below fair value)
Industry Position: 9.7% above the Medical Devices & Instruments median (#186 of 390)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
78GF Score
Get the complete analysis for REVXF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
